These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 22190967)
1. Type 1 diabetes immunological tolerance and immunotherapy. Chentoufi AA; Geenen V; Giannokakis N; Amrani A Clin Dev Immunol; 2011; 2011():103738. PubMed ID: 22190967 [No Abstract] [Full Text] [Related]
2. Antigen-based therapy for the treatment of type 1 diabetes. Tian J; Kaufman DL Diabetes; 2009 Sep; 58(9):1939-46. PubMed ID: 19720821 [No Abstract] [Full Text] [Related]
3. The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy. Fraker C; Bayer AL Curr Diab Rep; 2016 Nov; 16(11):109. PubMed ID: 27664042 [TBL] [Abstract][Full Text] [Related]
4. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Muir A; Schatz D; Maclaren N Diabetes Metab Rev; 1993 Dec; 9(4):279-87. PubMed ID: 7924825 [No Abstract] [Full Text] [Related]
5. Low-dose IL-2 as a therapeutic agent for tolerance induction. Malek TR; Pugliese A Immunotherapy; 2011 Nov; 3(11):1281-4. PubMed ID: 22053878 [No Abstract] [Full Text] [Related]
6. Immunotherapy of type 1 diabetes: where are we and where should we be going? Luo X; Herold KC; Miller SD Immunity; 2010 Apr; 32(4):488-99. PubMed ID: 20412759 [TBL] [Abstract][Full Text] [Related]
7. [Could we cure type 1 diabetes by stimulating T(reg)?]. Grinberg-Bleyer Y; Baeyens A; Piaggio E; Salomon BL Med Sci (Paris); 2011 May; 27(5):471-2. PubMed ID: 21609664 [No Abstract] [Full Text] [Related]
8. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Wang B; Tisch R Immunol Res; 2008; 42(1-3):246-58. PubMed ID: 19052699 [TBL] [Abstract][Full Text] [Related]
9. Bioengineering strategies for inducing tolerance in autoimmune diabetes. Baekkeskov S; Hubbell JA; Phelps EA Adv Drug Deliv Rev; 2017 May; 114():256-265. PubMed ID: 28625830 [TBL] [Abstract][Full Text] [Related]
10. Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes. Nikolic T; Zwaginga JJ; Uitbeijerse BS; Woittiez NJ; de Koning EJ; Aanstoot HJ; Roep BO Lancet Diabetes Endocrinol; 2020 Jun; 8(6):470-472. PubMed ID: 32723484 [No Abstract] [Full Text] [Related]
11. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Waldron-Lynch F; Herold KC Endocrinol Metab Clin North Am; 2009 Jun; 38(2):303-17, viii. PubMed ID: 19328413 [TBL] [Abstract][Full Text] [Related]
13. The potential role of dendritic cells in the therapy of Type 1 diabetes. Lee CN; Lew AM; Wu L Immunotherapy; 2013 Jun; 5(6):591-606. PubMed ID: 23725283 [TBL] [Abstract][Full Text] [Related]
15. Rational development of antigen-specific therapies for type 1 diabetes. Fousteri G; Bresson D; von Herrath M Adv Exp Med Biol; 2007; 601():313-9. PubMed ID: 17713020 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus. Phillips BE; Giannoukakis N; Trucco M Pediatr Endocrinol Rev; 2008 Jun; 5(4):873-9. PubMed ID: 18552749 [TBL] [Abstract][Full Text] [Related]